Zobrazeno 71 - 80
of 2 110
pro vyhledávání: ''
Publikováno v:
Breast Cancer Research and Treatment. 180:481-490
Breast cancer is a major public health concern worldwide and shows significant heterogeneity between male and female. Knowing the global incidence landscape in both sexes is critical for the breast cancer prevention and the reduction in disease burde
Autor:
Gerhard Schoen, C Noebel, T Schroeder, Jan Felix Kuhne, Hannes Leischner, Paul Bittrich, Jens Fiehler, Susanne Gellißen, Julian I. Schroeder
Publikováno v:
Journal of Neuro-Oncology
Purpose Prior reports on the location and sizes of brain metastases almost entirely focus on patients with primary breast and pulmonary cancer. This is the first study comparing multiple other types of cancer that metastasize to the brain. Methods Th
Autor:
E. Shelley Hwang, Terry Hyslop, Rachel A. Greenup, Jennifer K. Plichta, Rebecca Vernon, Oluwadamilola M. Fayanju, Samantha M. Thomas, Laura H. Rosenberger
Publikováno v:
Breast Cancer Res Treat
BACKGROUND: Given presumed differences in disease severity between young (≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extre
Publikováno v:
Breast Cancer Research and Treatment. 180:87-95
Squamous cell carcinoma (SCC) of the breast is a rare entity of breast cancer, with a very poor prognosis, and whose pathophysiology is still unwell established. Therapeutic management is very heterogeneous due to its incomplete understanding. Nevert
Publikováno v:
Clinical & Experimental Metastasis
Metastatic spinal cord compression (MSCC) is a frequent phenomenon in advanced tumor diseases with often severe neurological impairments. Affected patients are often treated by decompressive laminectomy. To assess the impact of this procedure on Karn
Autor:
Jeong Eon Lee, Byung Joo Chae, Jonghan Yu, Jai Min Ryu, Seok Jin Nam, Seok Won Kim, Se Kyung Lee
Publikováno v:
Japanese Journal of Clinical Oncology. 50:104-113
Objective Demands for genetic counseling with BRCA1/2 examination have markedly increased. Accordingly, the incidence of uninformative results on BRCA1/2 mutation status has also increased. Because most patients examined for BRCA1/2 mutation have a h
Autor:
Tuya Pal, Christina E. Bailey, Wei Zheng, Ingrid A. Mayer, Xiao-Ou Shu, Ingrid M. Meszoely, Ben Ho Park, Fei Wang, Sonya Reid
Publikováno v:
Clin Cancer Res
Purpose: Prognostic value of Oncotype DX Breast Recurrence Score (RS) in male patients with breast cancer is understudied. We evaluated associations of RS with overall mortality in male patients with breast cancer and compared it with female counterp
Autor:
Pernilla Olsson, Hilde Lurås, Teresia Wangensteen, Tone Bøe Aaman Vamre, Berit Gravdehaug, Eli Marie Grindedal, Lovise Maehle, Ellen Schlichting, Cecilie Heramb, Kjersti Jørgensen
Publikováno v:
Familial Cancer
Studies have shown that a significant number of eligible breast cancer patients are not offered genetic testing or referral to genetic counseling. To increase access to genetic testing in South Eastern Norway, testing has since 2014 been offered dire
Autor:
Komal Jhaveri, David M. Hyman, Richard Bryce, Melanie E. Dujka, Sarina Anne Piha-Paul, David I. Quinn, Ingrid A. Mayer, Cristina Saura, David B. Solit, Gary A. Ulaner, Seta Shahin, Ben Stone, Grace Mann, Funda Meric-Bernstam
Publikováno v:
Clin Cancer Res
Purpose: To determine whether FDG PET can expand eligibility in biomarker-selected clinical trials by providing a means to quantitate response in patients with non-assessable disease by RECIST. Experimental Design: SUMMIT (NCT01953926) is a multicent
Autor:
Prabhat Singh Malik, S V Suryanarayana Deo, Ajay Gogia, Sandeep Mathur, Rakesh K. Phulia, Dayanand Sharma, Sanjay Thulkar
Publikováno v:
Journal of Global Oncology
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
PURPOSE Biomarker—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/ neu) —discordance plays an essential role in the management and prognosis of patients with metastatic breast cancer. Rates o